Purchase this article with an account.
C.P. Jaime–Fonseca, III, E. López–Star, F. Martínez–Castro, T. Váldez–González; Methotrexate Therapy For Clasic Pars Planitis . Invest. Ophthalmol. Vis. Sci. 2006;47(13):2432.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate usefullness and security of methotrexate in pars planitis patients resistent to conventional therapy. Design: Prospective, comparative, longitudinal and experimental.
Material and Methods: :
We included pars planitis patients resistent to conventional antinflamatory therapy from april 2004 to octuber 2005. They recived methotrexate 5 mg weekly. Vitreous cells were assessed at each visit as well as best corrected visual acuity and liver function before an after the treatment.
Twenty three patients (46 eyes) were included. Fourteen men (61%), from 5 to 25 years old (11±5 years). 15 patients had pars planitis and or steroids complications before treatment with methotrexate: lens opacity 27 eyes, posterior sinequiae 11 eyes, band keratopathy 16 eyes, vitreous hemorrhage, macular edema, macular hole in 5 eyes. At the end of follow up 43 eyes (94%) improved vitreous cells. In fourteen patients (61%) inflammatory activity was eliminated. Liver function was affected in 7 patients but only one requires to stop treatment.
Methotrexate is and ussefull option of patients with pars planitis unresponsive to conventional therapy, with few adverse effects. Keys words: pars planitis, methotrexate, vitreous cells.
This PDF is available to Subscribers Only